Brief: Cti Biopharma Announces Acceptance Of NDA Granted With Priority Review Of Pacritinib For Treatment Of Patients With Myelofibrosis
01/06/2021 12:13
June 1 (Reuters) - CTI Biopharma Corp CTIC.O :
* CTI BIOPHARMA ANNOUNCES ACCEPTANCE OF NDA GRANTED WITH
PRIORITY
REVIEW OF PACRITINIB FOR TREATMENT OF PATIENTS WITH
MYELOFIBROSIS
* CTI BIOPHARMA CORP - PDUFA ACTION DATE NOVEMBER 30, 2021
* CTI BIOPHARMA CORP - FDA IS NOT CURRENTLY PLANNING TO HOLD
AN
ADVISORY COMMITTEE MEETING TO DISCUSS NDA.
Source text for Eikon: ID:nPn8CCpkDa
Further company coverage: CTIC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CTI Biopharma
See all newsBrief: CTI Biopharma Cancels 2023 Annual Meeting Of Stockholders
U.S. RESEARCH ROUNDUP-Albemarle, Ellington Financial, Savara
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
U.S. STOCKS ON THE MOVE-First Citizens BancShares, Sarepta, Celsius Holdings
U.S. STOCKS ON THE MOVE-Taboola, US banks, Copper miners